Cargando…
Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer
BACKGROUND: Prostate cancer is one of the most prevalent cancers in males in the United States and amongst the leading causes of cancer related deaths. A particularly virulent form of this disease is castration-resistant prostate cancer (CRPC), where patients no longer respond to medical or surgical...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374594/ https://www.ncbi.nlm.nih.gov/pubmed/28361666 http://dx.doi.org/10.1186/s12859-017-1522-2 |
_version_ | 1782518921045213184 |
---|---|
author | Arshad, Osama Ali Datta, Aniruddha |
author_facet | Arshad, Osama Ali Datta, Aniruddha |
author_sort | Arshad, Osama Ali |
collection | PubMed |
description | BACKGROUND: Prostate cancer is one of the most prevalent cancers in males in the United States and amongst the leading causes of cancer related deaths. A particularly virulent form of this disease is castration-resistant prostate cancer (CRPC), where patients no longer respond to medical or surgical castration. CRPC is a complex, multifaceted and heterogeneous malady with limited standard treatment options. RESULTS: The growth and progression of prostate cancer is a complicated process that involves multiple pathways. The signaling network comprising the integral constituents of the signature pathways involved in the development and progression of prostate cancer is modeled as a combinatorial circuit. The failures in the gene regulatory network that lead to cancer are abstracted as faults in the equivalent circuit and the Boolean circuit model is then used to design therapies tailored to counteract the effect of each molecular abnormality and to propose potentially efficacious combinatorial therapy regimens. Furthermore, stochastic computational modeling is utilized to identify potentially vulnerable components in the network that may serve as viable candidates for drug development. CONCLUSION: The results presented herein can aid in the design of scientifically well-grounded targeted therapies that can be employed for the treatment of prostate cancer patients. |
format | Online Article Text |
id | pubmed-5374594 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53745942017-03-31 Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer Arshad, Osama Ali Datta, Aniruddha BMC Bioinformatics Research BACKGROUND: Prostate cancer is one of the most prevalent cancers in males in the United States and amongst the leading causes of cancer related deaths. A particularly virulent form of this disease is castration-resistant prostate cancer (CRPC), where patients no longer respond to medical or surgical castration. CRPC is a complex, multifaceted and heterogeneous malady with limited standard treatment options. RESULTS: The growth and progression of prostate cancer is a complicated process that involves multiple pathways. The signaling network comprising the integral constituents of the signature pathways involved in the development and progression of prostate cancer is modeled as a combinatorial circuit. The failures in the gene regulatory network that lead to cancer are abstracted as faults in the equivalent circuit and the Boolean circuit model is then used to design therapies tailored to counteract the effect of each molecular abnormality and to propose potentially efficacious combinatorial therapy regimens. Furthermore, stochastic computational modeling is utilized to identify potentially vulnerable components in the network that may serve as viable candidates for drug development. CONCLUSION: The results presented herein can aid in the design of scientifically well-grounded targeted therapies that can be employed for the treatment of prostate cancer patients. BioMed Central 2017-03-22 /pmc/articles/PMC5374594/ /pubmed/28361666 http://dx.doi.org/10.1186/s12859-017-1522-2 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Arshad, Osama Ali Datta, Aniruddha Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer |
title | Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer |
title_full | Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer |
title_fullStr | Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer |
title_full_unstemmed | Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer |
title_short | Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer |
title_sort | towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374594/ https://www.ncbi.nlm.nih.gov/pubmed/28361666 http://dx.doi.org/10.1186/s12859-017-1522-2 |
work_keys_str_mv | AT arshadosamaali towardstargetedcombinatorialtherapydesignforthetreatmentofcastrationresistantprostatecancer AT dattaaniruddha towardstargetedcombinatorialtherapydesignforthetreatmentofcastrationresistantprostatecancer |